Oppenheimer raises Savara stock price target to $6 on BLA resubmission plans

Oppenheimer raised its price target on Savara (SVRA) to $6.00 from $5.00, maintaining an Outperform rating, as the company has aligned with the FDA on Chemistry, Manufacturing, and Controls (CMC) requirements for MOLBREEVI's Biologics License Application (BLA) resubmission, now slated for December 2025. This progress, including securing FUJIFILM as a new drug substance manufacturer, addresses prior regulatory setbacks and positions MOLBREEVI for potential August 2026 approval, given its robust Phase 3 data and significant commercial opportunity in the unmet medical need of autoimmune pulmonary alveolar proteinosis (aPAP).

Analysis

Oppenheimer has raised its price target on Savara (SVRA) to $6.00 from $5.00, maintaining an Outperform rating, following a significant de-risking of the regulatory pathway for its key drug candidate, MOLBREEVI. This analyst optimism, which contributed to a 14% stock gain over the past week, stems from Savara's alignment with the FDA on the Chemistry, Manufacturing, and Controls (CMC) data required for a Biologics License Application (BLA) resubmission. The company has addressed a prior 'Refusal to File' letter by contracting FUJIFILM as its new drug substance manufacturer and has established a clear timeline, targeting a BLA resubmission in December 2025. This sets the stage for a potential U.S. approval by August 2026, with subsequent filings in Europe and the UK planned for Q1 2026. The commercial opportunity is underpinned by robust Phase 3 data and an unmet need in autoimmune pulmonary alveolar proteinosis (aPAP), with an estimated 1,000 patients at launch. However, the situation is framed by historical regulatory setbacks and divergent analyst opinions, with firms like H.C. Wainwright and Evercore ISI holding more conservative Neutral/$2 and In Line/$2 ratings, respectively, in contrast to Guggenheim's Buy/$8 target.

Key Decisions for Investors

• Investors with a long-term horizon and high risk tolerance could interpret the clarified FDA regulatory timeline as a major de-risking event, justifying a position based on the potential August 2026 approval catalyst.
• It is critical to monitor the company's execution on its manufacturing plan with FUJIFILM and any further FDA correspondence, as these represent the primary risks ahead of the December 2025 resubmission.
• Considering the stock's recent 14% appreciation and the wide dispersion in analyst price targets ranging from $2 to $8, investors should weigh Oppenheimer's bullish case against the more cautious stances and the long lead time to potential revenue.